Bayer AG
XETRA:BAYN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.315
44.26
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BAYN stock under the Base Case scenario is 117.217 EUR. Compared to the current market price of 26.265 EUR, Bayer AG is Undervalued by 78%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bayer AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BAYN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Bayer AG, a German multinational corporation, stands as a pivotal player in the fields of pharmaceuticals, consumer health, agricultural products, and biotechnology. Founded in 1863, Bayer has transformed over the decades into a global powerhouse, renowned for its commitment to innovation and sustainability. The company is best known for its development of influential medications while also offering a broad portfolio of consumer health products, including over-the-counter medications and nutritional supplements. Bayer’s robust research and development arm fuels its growth, focusing on areas such as oncology, cardiology, and women's health, which showcases its dedication to addressing signifi...
Bayer AG, a German multinational corporation, stands as a pivotal player in the fields of pharmaceuticals, consumer health, agricultural products, and biotechnology. Founded in 1863, Bayer has transformed over the decades into a global powerhouse, renowned for its commitment to innovation and sustainability. The company is best known for its development of influential medications while also offering a broad portfolio of consumer health products, including over-the-counter medications and nutritional supplements. Bayer’s robust research and development arm fuels its growth, focusing on areas such as oncology, cardiology, and women's health, which showcases its dedication to addressing significant health challenges.
In addition to its pharmaceutical segment, Bayer operates a thriving Crop Science division, which aims to enhance agricultural productivity and sustainability. By integrating cutting-edge biotechnology with traditional farming techniques, Bayer helps farmers combat pests and improve crop yields while reducing environmental impact. As an investor, you'll be interested to know that Bayer's recent strategic initiatives, including the successful acquisition of Monsanto, have strengthened its position in the agricultural sector, opening new avenues for growth. With an eye on long-term value creation, Bayer is not just positioned to tackle immediate market demands but also to lead in addressing global challenges such as food security and healthcare accessibility, making it a compelling consideration for any thoughtful investor looking to diversify within health and agriculture.
Bayer AG is a global enterprise with core business segments primarily categorized into three main areas:
-
Pharmaceuticals: This segment focuses on the research, development, manufacturing, and marketing of prescription medications. Bayer specializes in several therapeutic areas, including cardiology, oncology, gynecology, hematology, ophthalmology, and radiology. Notable products include anticoagulants like Xarelto and cancer treatments.
-
Consumer Health: Bayer's Consumer Health division produces over-the-counter (OTC) products that enhance health and well-being. This includes a broad range of categories like dietary supplements, analgesics (e.g., Aspirin), dermatology products, and other healthcare solutions aimed at consumers directly.
-
Crop Science: Bayer Crop Science is a leader in agriculture, specializing in crop protection products, seeds, and crop traits. This segment focuses on developing innovative solutions for sustainable agriculture, including pesticides, herbicides, and biotechnology products. This division addresses challenges such as pest management and increasing food production.
In addition to these core segments, Bayer also emphasizes sustainability and innovation across its operations, aiming to create benefits for society and the environment, in line with its mission to advance health and nutrition.
Bayer AG, a global leader in life sciences, particularly in pharmaceuticals, consumer health, agriculture, and biotechnology, possesses several unique competitive advantages over its rivals:
-
Strong Brand Equity: Bayer has a long-standing reputation and brand loyalty built over more than 150 years. Its brands, such as Aspirin and Claritin, are well recognized worldwide.
-
Diverse Product Portfolio: Bayer's extensive range of products across various segments (pharmaceuticals, consumer health, crop science, and animal health) enables it to mitigate risks and capitalize on different market opportunities.
-
Research and Development: Bayer invests significantly in R&D, which allows it to innovate and stay at the forefront of scientific advancements. Its commitment to developing new therapies and agricultural solutions enhances its product pipeline.
-
Global Presence: Bayer operates in numerous countries, providing a broad geographical footprint that allows it to tap into different markets and reduce dependence on any single economy.
-
Strategic Acquisitions: The company has a history of successful acquisitions, such as the acquisition of Monsanto, which has strengthened its position in the agricultural sector and enhanced its capabilities in biotechnology.
-
Sustainability Focus: Bayer emphasizes sustainable practices, especially in agriculture, developing solutions that help farmers increase yield while minimizing environmental impact. This aligns with the growing global demand for sustainable practices.
-
Strong Financial Position: Bayer's financial strength allows it to invest in growth opportunities, pursue research initiatives, and withstand market fluctuations better than many competitors.
-
Regulatory Expertise: Given the highly regulated nature of the pharmaceutical and agricultural sectors, Bayer's expertise in navigating regulatory environments can be a significant competitive advantage.
-
Collaborations and Partnerships: Bayer actively collaborates with academic institutions, biotechnology firms, and other organizations to foster innovation and accelerate product development.
-
Digital Transformation: Bayer is investing in digital technologies and smart farming solutions to enhance its product offerings and improve its operational efficiencies.
By leveraging these competitive advantages, Bayer AG can maintain its leadership position in the life sciences sector and continue to innovate in response to market demands.
Bayer AG, a global leader in pharmaceuticals, consumer health, and agrochemicals, faces several risks and challenges that could impact its business in the near future. These include:
-
Regulatory Challenges: Bayer operates in heavily regulated industries. Changes in regulations, stricter compliance standards, or unfavorable rulings can affect product approvals, operations, and market access.
-
Litigation Risks: Bayer has faced significant legal challenges, particularly related to its acquisition of Monsanto and products like glyphosate. Ongoing lawsuits and potential settlements pose financial and reputational risks.
-
Market Competition: The pharmaceutical and agrochemical industries face intense competition from both established companies and new entrants. Innovations from competitors could erode Bayer's market share.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by the COVID-19 pandemic and geopolitical tensions, could affect Bayer's ability to manufacture and distribute its products effectively.
-
Environmental and Social Governance (ESG) Expectations: Increasing scrutiny on environmental practices and social responsibility may lead to higher operational costs or necessitate changes in business practices to meet stakeholder expectations.
-
Economic Fluctuations: Economic instability, inflation, and currency fluctuations can impact consumer spending and demand for Bayer's products, particularly in emerging markets.
-
Research and Development (R&D) Risks: Bayer invests heavily in R&D, but the pharmaceutical pipeline can be unpredictable. Failed trials or delays can affect future revenue streams.
-
Data Privacy and Cybersecurity: As the reliance on digital systems increases, so does the risk of data breaches and cyberattacks, which can compromise sensitive information and disrupt operations.
-
Reputation Management: Given past controversies, Bayer needs to manage its reputation carefully. Negative public perception can impact sales, partnerships, and overall market position.
-
Sustainability Challenges: As the world shifts towards sustainability, Bayer must innovate and adapt its product lines and practices to meet consumer demand and regulatory expectations for sustainability.
Understanding these challenges is crucial for investors and stakeholders as they navigate Bayer’s future prospects.
Revenue & Expenses Breakdown
Bayer AG
Balance Sheet Decomposition
Bayer AG
Current Assets | 40.1B |
Cash & Short-Term Investments | 10B |
Receivables | 17B |
Other Current Assets | 13.1B |
Non-Current Assets | 79.7B |
Long-Term Investments | 3.2B |
PP&E | 13.5B |
Intangibles | 55.9B |
Other Non-Current Assets | 7.2B |
Current Liabilities | 31.6B |
Accounts Payable | 6.1B |
Other Current Liabilities | 25.4B |
Non-Current Liabilities | 52.6B |
Long-Term Debt | 37.4B |
Other Non-Current Liabilities | 15.2B |
Earnings Waterfall
Bayer AG
Revenue
|
47.1B
EUR
|
Cost of Revenue
|
-19.8B
EUR
|
Gross Profit
|
27.4B
EUR
|
Operating Expenses
|
-25.1B
EUR
|
Operating Income
|
2.2B
EUR
|
Other Expenses
|
-3.5B
EUR
|
Net Income
|
-1.3B
EUR
|
Free Cash Flow Analysis
Bayer AG
EUR | |
Free Cash Flow | EUR |
In Q2, revenue rose by 3% to €11.1 billion, despite a 16% drop in EBITDA to €2.1 billion, driven by unfavorable product mix and higher incentive provisions. Free cash flow improved significantly to €1.3 billion. Crop Science saw a 1% sales increase, with strong soybean growth mitigating corn declines. Pharma grew by 4%, led by new products like Nubeqa and Kerendia. Consumer Health returned to growth, driven by innovations in Dermatology and Digestive Health. Full-year guidance was confirmed with an expected sales increase of 0% to 3% in Pharma and pressure from generics on Xarelto.
What is Earnings Call?
BAYN Profitability Score
Profitability Due Diligence
Bayer AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Bayer AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
BAYN Solvency Score
Solvency Due Diligence
Bayer AG's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Bayer AG's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAYN Price Targets Summary
Bayer AG
According to Wall Street analysts, the average 1-year price target for BAYN is 33.428 EUR with a low forecast of 25.25 EUR and a high forecast of 64.05 EUR.
Dividends
Current shareholder yield for BAYN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.
Contact
IPO
Employees
Officers
The intrinsic value of one BAYN stock under the Base Case scenario is 117.217 EUR.
Compared to the current market price of 26.265 EUR, Bayer AG is Undervalued by 78%.